Collaborations

Cenix BioScience and Merck KGaA sign framework agreement for RNAi-based drug discovery

Published in Gene Therapy Weekly, October 26th, 2006

Cenix BioScience GmbH (Dresden) and Merck KGaA (Darmstadt, Germany) announced that they have signed a framework research agreement securing Cenix services to enhance and accelerate Merck target discovery and validation efforts in oncology, with an option to expand in several human disease programs.

Cenix will apply its well-established expertise combining high throughput (HT), genome-scale screening applications of RNAi with high content phenotypic analyses in cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.

By yielding direct and highly predictive insights into the cellular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-10-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry